托瑞米芬和他莫昔芬对MCF7/ADR多药耐药的逆转作用

被引：4

作者：

王红霞

张凤春

楼丽广

唐卫东

机构：

[1] 上海交通大学医学院附属仁济医院肿瘤科

来源：

现代肿瘤医学 | 2007年 / 09期

关键词：

托瑞米芬; 多药耐药; P糖蛋白;

D O I：

暂无

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

摘要：

目的:研究托瑞米芬(toremifene,TOR)和他莫昔芬(tamoxifen,TAM)对乳腺癌耐阿霉素细胞株MCF7/ADR多药耐药的逆转作用及其可能作用机制。方法:采用SRB法测量TOR、TAM对MCF7/ADR细胞的耐药逆转倍数;荧光显微镜、流式细胞仪测定加入TOR、TAM前后耐药细胞内荧光含量表达变化;Westernblotting检测TOR、TAM对P-gp表达的影响。结果:(5、10、20)μmol/L的TOR和TAM对MCF7/ADR耐药的逆转倍数分别为(1.5、7.0、35.4)倍和(2.0、5.4、30.7)倍,而对MCF7/S细胞没有显著性作用。加入TOR、TAM后,MCF7/ADR细胞内ADR荧光的呈现由核外进入核内,荧光含量亦具浓度依赖性提高。MCF7/S细胞P-gp表达阴性,而MCF/ADR细胞P-gp表达阳性。TOR[(5、10、20)μmol/L]与TAM[(5、10)μmol/L]对MCF7/ADR细胞株中的P-gp表达未产生显著性抑制作用。结论:TOR可明显逆转MCF7/ADR细胞株对ADR的耐药性,增强其细胞毒作用,逆转强度与TAM相当。其机制可能是通过对P-gp结构功能的调控来逆转耐药性,而不是通过下调MDR1基因的蛋白水平表达。

引用

页码：1216 / 1221

页数：6

共 10 条

[1]

Drug resistance in chemotherapy for breast cancer[J] . Toshiaki Saeki,Takashi Tsuruo,Wakao Sato,Kiyoshiro Nishikawsa. &nbspCancer Chemotherapy and Pharmacology . 2005 (1)

[2] Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine [J].

Braybrooke, JP ;

Vallis, KA ;

Houlbrook, S ;

Rockett, H ;

Ellmén, J ;

Anttila, M ;

Ganesan, TS ;

Harris, AL ;

Talbot, DC .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (01) :27-34

[3]

Drug resistance in chemotherapy for breast cancer. Saeki T,Tsuruo T,Sato W,et al. Cancer Chemother . 2005

[4]

Acase of breast caner pa-tient of CAF(cyclophosphamid,adriamycin,5-fluorouracil)re-sistant lung metastasis with remarkable response to reverse drug-resistance by toremifene. Kusama M,Kaise H,Nakayama S,et al. Gan To Kagaku Ryono . 1999

[5]

Toremifene sensitized the effect of adriamycin on human breast cancer cell lines. Nakagomi H,Furuya K,Hagiwara J,et al. Gan To Kagaku Ryono . 1998

[6]

Comb inedeffects of torem ifene and paclitaxel on human breast cancer celllines. Maruyama S,Kuroiwa S,Saimoto A,N ish ikawa K. Gan To Kagaku Ryono . 2003

[7]

99m Tc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer. Mubashar M,Harrington KJ,Chaudhary KS,et al. Journal of Nuclear Medicine, The . 2002

[8]

Differential effects of toremifene on doxorubicin,vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing breast and head and neck cancer cell lines. Mubashar M,Harrington KJ,Chaudhary KS,et al. Acta Oncologica . 2004

[9]

Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antago-nists and agonists. Sugimoto Y,Tsukahara S,Imai Y,et al. Molecular Cancer Therapeutics . 2003

[10]

Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine. Braybrooke JP,Vallis KA,Houlbrook S,et al. Cancer Chemotherapy and Pharmacology . 2000

← 1 →